
Dr Lal PathLabs Share Price Rises 4.27% After Q1 FY27 Results
Dr Lal PathLabs share price gained 4.27% on Q1 results. Dr Lal PathLabs posted its highest ever quarterly profit in Q1 FY27, with net profit up 27.2 percent year on year to Rs 170 crore on revenue of
Updated: 27 Jul 2026 • 11:16 am
Posted by:

Dr Lal PathLabs share price gained 4.27%, moving from Rs 1,687.10 to Rs 1,759.20, after the company’s Q1 FY27 results. Dr Lal PathLabs posted its highest ever quarterly profit in Q1 FY27, with net profit up 27.2 percent year on year to Rs 170 crore on revenue of Rs 798 crore, up 19.1 percent.
The move reflects how the market weighed Dr Lal PathLabs’s quarterly numbers against broader sector and valuation context on results day.
Click Here – Get Free Investment Predictions
Dr Lal PathLabs Q1 FY27 Results: Key Numbers
The board also declared an interim dividend of Rs 5 per share, adding to positive sentiment around the results.
| Metric | Detail |
|---|---|
| Dr Lal PathLabs | Q1 FY27 results |
| Share Price Reaction | Up 4.27% (Rs 1,687.10 to Rs 1,759.20) |
Univest – A SEBI-Registered Investment Advisor
Investors tracking the Dr Lal PathLabs share price should watch management commentary and subsequent brokerage notes for a fuller read on the quarter.
The stock has now moved from Rs 1,687.10 to Rs 1,759.20 between 23 July and 24 July, a period that captures the market’s initial digestion of the quarterly numbers.
Download the Univest iOS App or Univest Android App to track live Dr Lal PathLabs share price movements.
Why Did the Stock React This Way
The Dr Lal PathLabs share price gained 4.27% as investors weighed the Q1 FY27 print against expectations, valuation and broader market conditions on the day of the results.
Markets typically weigh both the headline profit and revenue trend alongside management’s forward commentary, and Dr Lal PathLabs’s reaction on the day reflects that broader assessment rather than any single data point in isolation.
Conclusion
Dr Lal PathLabs share price gained 4.27% after the company’s Q1 FY27 results. Dr Lal PathLabs posted its highest ever quarterly profit in Q1 FY27, with net profit up 27.2 percent year on year to Rs 170 crore on revenue of Rs 798 crore, up 19.1 percent. Investors should track the company’s subsequent brokerage commentary and consult a SEBI-registered advisor before making investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions FAQs
Why did the Dr Lal PathLabs share price move after Q1 results?
Ans. The Dr Lal PathLabs share price gained 4.27 percent, moving from Rs 1,687.10 to Rs 1,759.20, after Dr Lal PathLabs released its Q1 FY27 results. Dr Lal PathLabs posted its highest ever quarterly profit in Q1 FY27, with net profit up 27.2 percent year on year to Rs 170 crore on revenue of Rs 798 crore, up 19.1 percent.
What was Dr Lal PathLabs’s Q1 FY27 result highlight?
Ans. Dr Lal PathLabs posted its highest ever quarterly profit in Q1 FY27, with net profit up 27.2 percent year on year to Rs 170 crore on revenue of Rs 798 crore, up 19.1 percent.
How much did the Dr Lal PathLabs share price move around the results?
Ans. The Dr Lal PathLabs share price moved up 4.27 percent from Rs 1,687.10 to Rs 1,759.20 around the Q1 FY27 results.
Should investors buy Dr Lal PathLabs after this move?
Ans. Investors should review the company’s full Q1 FY27 results, management commentary and valuation before making any decision, and are advised to consult a SEBI-registered advisor.
Where can I track live Dr Lal PathLabs updates?
Ans. Live Dr Lal PathLabs share price updates, charts and financials are available on the Univest platform and app.
What should investors watch next for Dr Lal PathLabs?
Ans. Investors should track subsequent brokerage notes, management commentary on the earnings call, and the company’s performance in the following quarter for further clarity on the Dr Lal PathLabs share price trend.
Recent Articles

IDFC First Bank vs IndusInd Bank Business Model: Which Private Banks Wins
27 July 2026

Bandhan Bank vs IDFC First Bank Business Model: Which Private Banks Wins
27 July 2026

Sun Pharma vs Lupin Business Model: Which Domestic Pharmaceuticals Wins
27 July 2026

Cipla vs Lupin Business Model: Which Domestic Pharmaceuticals Wins
27 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
IDFC First Bank vs IndusInd Bank Business Model: Which Private Banks Wins
Bandhan Bank vs IDFC First Bank Business Model: Which Private Banks Wins
Sun Pharma vs Lupin Business Model: Which Domestic Pharmaceuticals Wins
Cipla vs Lupin Business Model: Which Domestic Pharmaceuticals Wins
Adani Enterprises vs Adani Power Business Model: Which Adani Group Wins
Popular this week
IDFC First Bank vs IndusInd Bank Business Model: Which Private Banks Wins
Bandhan Bank vs IDFC First Bank Business Model: Which Private Banks Wins
Sun Pharma vs Lupin Business Model: Which Domestic Pharmaceuticals Wins
Cipla vs Lupin Business Model: Which Domestic Pharmaceuticals Wins
Adani Enterprises vs Adani Power Business Model: Which Adani Group Wins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





